Sanara MedTech Narrows Q2 Loss on Strong Revenue Growth

TL;DR

**SMTI's revenue growth is impressive, but rising debt and persistent losses mean it's a high-risk, high-reward play for now.**

AI Summary

Sanara MedTech Inc. (SMTI) reported a net loss of $2.01 million for the three months ended June 30, 2025, an improvement from a $3.53 million net loss in the same period of 2024. For the six months ended June 30, 2025, the net loss was $5.55 million, slightly higher than the $5.33 million loss in the prior year. Revenue saw significant growth, reaching $25.83 million for the quarter, up 28.1% from $20.16 million in Q2 2024, and $49.26 million for the six months, a 27.3% increase from $38.70 million in H1 2024. Gross profit also increased to $23.89 million for the quarter and $45.49 million for the six months. However, operating expenses rose to $23.92 million for the quarter and $47.60 million for the six months, driven by increased selling, general, and administrative expenses, and research and development. Long-term debt significantly increased to $44.22 million as of June 30, 2025, from $30.69 million at December 31, 2024, primarily due to loan proceeds of $12.02 million. The company also invested $3.54 million in equity securities and $2.12 million in the CarePICS acquisition during the first half of 2025, indicating strategic expansion in its Tissue Health Plus segment.

Why It Matters

Sanara MedTech's robust revenue growth, up 28.1% year-over-year in Q2 2025, signals strong market adoption for its surgical and wound care products, which is crucial for investor confidence in a competitive medical technology landscape. The strategic investments in equity securities and the CarePICS acquisition highlight the company's commitment to expanding its Tissue Health Plus segment and value-based wound care programs, potentially disrupting traditional healthcare models. However, the significant increase in long-term debt and continued net losses, despite narrowing, warrant close attention as they could impact future profitability and financial flexibility, especially when competing with larger, more established medical device companies.

Risk Assessment

Risk Level: high — The company reported a net loss of $5.55 million for the six months ended June 30, 2025, and its accumulated deficit reached $43.29 million. Long-term debt increased substantially to $44.22 million as of June 30, 2025, from $30.69 million at December 31, 2024, indicating increased leverage. These factors, combined with ongoing operating losses, suggest a high financial risk.

Analyst Insight

Investors should monitor Sanara MedTech's ability to translate its strong revenue growth into profitability and positive cash flow from operations. Evaluate the impact of the CarePICS acquisition and the Tissue Health Plus segment's value-based wound care programs on future financial performance and debt reduction. Consider the company's cash burn relative to its cash reserves of $16.96 million.

Financial Highlights

debt To Equity

N/A

revenue

$25.83M

operating Margin

-0.12%

total Assets

N/A

total Debt

$44.22M

net Income

-$2.01M

eps

N/A

gross Margin

92.49%

cash Position

$16.96M

revenue Growth

+28.1%

Revenue Breakdown

Key Numbers

• $25.83M — Net Revenue (Q2 2025) (Increased 28.1% from $20.16M in Q2 2024)
• $49.26M — Net Revenue (H1 2025) (Increased 27.3% from $38.70M in H1 2024)
• $(2.01M) — Net Loss (Q2 2025) (Improved from $(3.53M) in Q2 2024)
• $(5.55M) — Net Loss (H1 2025) (Slightly higher than $(5.33M) in H1 2024)
• $44.22M — Long-term Debt (Increased from $30.69M at Dec 31, 2024)
• $12.02M — Loan Proceeds (H1 2025) (Contributed to increased long-term debt)
• $2.12M — CarePICS Acquisition (H1 2025) (Cash used in investing activities)
• $3.54M — Investment in Equity Securities (H1 2025) (Cash used in investing activities)
• $16.96M — Cash (June 30, 2025) (Increased from $15.88M at Dec 31, 2024)
• $(0.64) — Net Loss Per Share (H1 2025) (Compared to $(0.62) in H1 2024)

Key Players & Entities

• Sanara MedTech Inc. (company) — Registrant and medical technology company
• CarePICS (company) — Acquired entity
• Tissue Health Plus (company) — Operating segment and subsidiary
• Rochal Technologies (company) — In-house research and development team
• The Nasdaq Capital Market (regulator) — Exchange where SMTI common stock is registered
• Precision Healing, Inc. (company) — Company merged with in April 2022
• Chief Executive Officer (person) — Chief operating decision maker
• $25,830,834 (dollar_amount) — Net Revenue for three months ended June 30, 2025
• $44,216,662 (dollar_amount) — Long-term debt as of June 30, 2025
• $16,958,744 (dollar_amount) — Cash as of June 30, 2025

FAQ

Risk Factors

• Increased Debt Load [high — financial]: Long-term debt has significantly increased to $44.22 million as of June 30, 2025, up from $30.69 million at December 31, 2024. This increase is primarily due to $12.02 million in new loan proceeds, raising concerns about leverage and future debt servicing capacity.
• Rising Operating Expenses [medium — operational]: Operating expenses grew to $23.92 million for Q2 2025 and $47.60 million for H1 2025. This rise is attributed to increased selling, general, and administrative (SG&A) expenses, as well as higher research and development (R&D) costs, potentially impacting profitability.
• Net Loss Trend [medium — financial]: Despite revenue growth, the company reported a net loss of $2.01 million for Q2 2025 and $5.55 million for H1 2025. While the quarterly loss improved year-over-year, the six-month loss is slightly higher, indicating ongoing profitability challenges.
• Integration of Acquisitions [medium — operational]: The company made strategic investments, including $2.12 million for the CarePICS acquisition and $3.54 million in equity securities in H1 2025. Successful integration of these investments is crucial for realizing expected synergies and growth, posing an operational risk if not managed effectively.

Industry Context

Sanara MedTech operates in the competitive medical technology sector, focusing on wound care and tissue health. The industry is characterized by rapid innovation, stringent regulatory oversight, and the need for significant R&D investment. Companies often pursue strategic acquisitions to expand their product portfolios and market reach, as seen with SMTI's CarePICS acquisition.

Regulatory Implications

As a medical technology company, SMTI is subject to rigorous regulatory scrutiny from bodies like the FDA. Compliance with evolving healthcare regulations, data privacy laws (e.g., HIPAA), and product safety standards are critical. Any failure to comply can result in significant fines, product recalls, and reputational damage.

What Investors Should Do

1. Monitor operating expense trends closely.
2. Evaluate the impact of increased debt.
3. Assess the ROI of strategic investments.
4. Analyze the path to profitability.

Key Dates

• 2025-06-30: End of Q2 2025 — Reported $25.83M in revenue and a net loss of $2.01M, showing revenue growth but continued net losses.
• 2025-06-30: Consolidated Balance Sheet Date — Reflected a significant increase in long-term debt to $44.22M and a cash position of $16.96M.
• 2025-01-01: Beginning of H1 2025 — Marked the start of a period with $49.26M in revenue and $5.55M in net loss, including strategic investments and acquisitions.
• 2024-12-31: End of Fiscal Year 2024 — Previous reporting period for balance sheet comparison, with long-term debt at $30.69M.

Glossary

Consolidated Statements of Operations

Financial statements that report a company's financial performance over a specific accounting period, including revenues, expenses, and net income or loss. (Provides the key figures for revenue, gross profit, operating expenses, and net loss for SMTI in Q2 and H1 2025.)

Consolidated Balance Sheets

Financial statements that report a company's assets, liabilities, and shareholders' equity at a specific point in time. (Shows the company's financial position, including its cash, debt levels, and equity, as of June 30, 2025, and December 31, 2024.)

Consolidated Statements of Cash Flows

Financial statements that report the cash generated and used by a company during a specific period, categorized into operating, investing, and financing activities. (Details how SMTI used cash for investments like acquisitions and equity securities, and how it raised funds through loans.)

Selling, General, and Administrative Expenses (SG&A)

Costs incurred by a company in the process of selling products or services, and for the general management of the business. (A significant component of SMTI's operating expenses, contributing to the increase in costs for Q2 and H1 2025.)

Research and Development (R&D)

Expenses incurred by a company for activities aimed at discovering new knowledge and developing new products or processes. (Another key driver of SMTI's increased operating expenses, indicating investment in future innovation.)

Year-Over-Year Comparison

Compared to the prior year, Sanara MedTech Inc. has demonstrated robust revenue growth, with Q2 2025 revenue up 28.1% to $25.83 million and H1 2025 revenue up 27.3% to $49.26 million. However, this top-line growth has been accompanied by a rise in operating expenses, leading to a net loss of $2.01 million in Q2 2025 (an improvement from $3.53 million in Q2 2024) and a slightly higher net loss of $5.55 million for H1 2025 compared to $5.33 million in H1 2024. A significant development is the increase in long-term debt to $44.22 million, up from $30.69 million at the end of 2024, driven by new loan proceeds and strategic investments.

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 par value SMTI The Nasdaq Capital M

Filing Documents

• form10-q.htm (10-Q) — 1277KB
• ex31-1.htm (EX-31.1) — 15KB
• ex31-2.htm (EX-31.2) — 16KB
• ex32-1.htm (EX-32.1) — 8KB
• ex32-2.htm (EX-32.2) — 8KB
• 0001493152-25-011885.txt ( ) — 7635KB
• smti-20250630.xsd (EX-101.SCH) — 55KB
• smti-20250630_cal.xml (EX-101.CAL) — 76KB
• smti-20250630_def.xml (EX-101.DEF) — 245KB
• smti-20250630_lab.xml (EX-101.LAB) — 496KB
• smti-20250630_pre.xml (EX-101.PRE) — 393KB
• form10-q_htm.xml (XML) — 1212KB

– Financial Information

Part I – Financial Information 3

Financial Statements

Item 1. Financial Statements 3 Consolidated Balance Sheets as of June 30, 2025 (Unaudited) and December 31, 2024 3 Consolidated Statements of Operations (Unaudited) for the Three and Six Months Ended June 30, 2025 and 2024 4 Consolidated Statements of Changes in Shareholders' Equity (Unaudited) for the Three and Six Months Ended June 30, 2025 and 2024 5 Consolidated Statements of Cash Flows (Unaudited) for the Six Months Ended June 30, 2025 and 2024 6 Notes to Unaudited Consolidated Financial Statements 7

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 34

Quantitative and Qualitative Disclosures about Market Risk

Item 3. Quantitative and Qualitative Disclosures about Market Risk 49

Controls and Procedures

Item 4. Controls and Procedures 49

– Other Information

Part II – Other Information 50

Legal Proceedings

Item 1. Legal Proceedings 50

Risk Factors

Item 1A. Risk Factors 50

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 50

Defaults Upon Senior Securities

Item 3. Defaults Upon Senior Securities 50

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 50

Other Information

Item 5. Other Information 50

Exhibits

Item 6. Exhibits 51

Signatures

Signatures 52 Sanara, Sanara MedTech, our logo and our other trademarks or service marks appearing in this report are the property of Sanara MedTech Inc. Trade names, trademarks and service marks of other companies appearing in this report are the property of their respective owners. Solely for convenience, the trademarks, service marks and trade names included in this report are without the , or other applicable symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensors to these trademarks, service marks and trade names. Unless otherwise indicated, "Sanara MedTech," "Sanara," the "Company," "our," "us," or "we," refer to Sanara MedTech Inc. and its consolidated subsidiaries. 2 Table of Contents Part I - Financial Information ITEM 1. FINANCIAL STATEMENTS SANARA MEDTECH INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS June 30, 2025 December 31, 2024 (Unaudited) Assets Current assets Cash $ 16,958,744 $ 15,878,295 Accounts receivable, net 11,989,698 12,408,819 Accounts receivable – related parties 9,081 40,566 Accounts receivable 9,081 40,566 Inventory, net 3,511,850 2,753,032 Convertible loan receivable - 1,101,478 Prepaid and other assets 1,200,083 1,123,798 Total current assets 33,669,456 33,305,988 Long-term assets Intangible assets, net 40,992,568 41,006,776 Goodwill 3,601,781 3,601,781 Investment in equity securities 10,515,812 8,297,223 Right of use assets – operating leases 1,088,149 1,447,907 Property and equipment, net 8,899,879 432,317 Total long-term assets 65,098,189 54,786,004 Total assets $ 98,767,645 $ 88,091,992 Liabilities and shareholders' equity Current liabilities Accounts payable $ 1,457,301 $ 1,499,764 Accounts payable – related parties 32,355 30,913 Accounts payable 32,355 30,913 Accrued bonuses and commissi

View Full Filing

View this 10-Q filing on SEC EDGAR